Detail akcie MaxCyte online

Business Summary: MaxCyte, Inc. is a commercial cell engineering company. The Company is focused on providing enabling platform technologies to advance the discovery, development and commercialization of cell therapeutics, including cell and gene therapies, and to support cell-based research and development. It has developed and commercialized its proprietary Flow Electroporation technology, which is used by biopharmaceutical companies in the complex engineering of a variety of cells. Its ExPERT platform is based on its Flow Electroporation technology, which has been designed to address this rapidly expanding cell therapy market and can be utilized across the continuum of the cell therapy sector, from discovery and development through commercialization of cell-based medicines. The ExPERT family of products includes four instruments, which are known as the ATx, STx, GTx and VLx, as well as a portfolio of proprietary related disposables and consumables.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, MaxCyte Inc revenues decreased 14% to $25.7M. Net loss increased 15% to $35M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Interest income decrease of 28% to $5.6M (income), Research and developmen increase of 4% to $15.8M (expense), Depreciation and amortization increase of 2% to $3.2M (expense).